

ALLERGAN INC  
Form 15-15D  
April 17, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION**  
**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934**  
**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Commission File Number 333-183092**

**ALLERGAN, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

**Morris Corporate Center**  
**400 Interpace Parkway**  
**Parsippany, New Jersey 07054**

(862) 261-7000

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**\$250,000,000 1.350% Notes due 2018**

**\$350,000,000 2.800% Notes due 2023**

(Title of each class of securities covered by this Form)

N/A

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	..
Rule 12g-4(a)(2)	..
Rule 12h-3(b)(1)(i)	..
Rule 12h-3(b)(1)(ii)	..
Rule 15d-6	x

Approximate number of holders of record as of the certification or notice date: \$250,000,000 1.350% Notes due 2018: seventy; \$350,000,000 2.800% Notes due 2023: sixty

Pursuant to the requirements of the Securities Exchange Act of 1934, Allergan, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: April 16, 2015

ALLERGAN, INC.

By: /s/ A. Robert D. Bailey

Name: A. Robert D. Bailey

Title: President and Chairman of the Board